SMTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Sanara Medtech Inc (SMTI) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive technical signals, neutral trading trends, absence of news catalysts, and weak financial performance despite revenue growth suggest waiting for a clearer entry point.
The technical indicators show a bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 24.841, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading below key pivot levels, with support at 19.291 and resistance at 21.942.
Revenue increased by 21.51% YoY in Q3 2025, and gross margin improved to 90.56%.
No recent news or significant trading trends from insiders or hedge funds.
In Q3 2025, revenue increased by 21.51% YoY to $26.33M. However, net income remains negative at -$30.41M, albeit improving by 964.16% YoY. EPS is still negative at -3.52, and gross margin improved slightly to 90.56%.
No analyst rating or price target changes available.
